Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-effica
Benefits of Drug Risk Aversion Calculation to Multiple Sclerosis Drug Choice and Patient Self-efficacy
What it found
The trial ended early for another reason (see below).
Reason given: Clinical workflow was too high
What was tested
Treatment tested
- Risk Aversion Calculator
What it measured
Main measures
Change from Baseline Disease Self-efficacy
Baseline and then at the conclusion of the initial 1 day visit
Other measures (4)
Time to new medication start
6 months
Medication adherence
At enrollment and at each subsequent visit for one year
Quality of life (reported by participants)Change from Baseline Disease Self-efficacy at 6 months
At enrollment and at 6 months post-visit
Change from Baseline Disease Self-efficacy at 12 months
At enrollment and at 12 months post-visit
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Be at least 18 years old * Be able to read and speak English * Be currently treated or starting treatment with an MS disease modifying medication
Exclusion criteria
* All of the inclusion criteria must be met. If they cannot be met, then they are excluded from the study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The investigators seek to determine if the use of a Side Effect Aversion Calculator helps patients with multiple sclerosis (MS) more comfortably and rapidly identify the disease modifying drug (DMD) that is best suited for the patient.
Loading reviews and guidelines…
History
Started
Mar 2018
Main results due
Mar 2019
Finished
Mar 2019